Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by HomerAndCompanyon Mar 17, 2023 9:08am
232 Views
Post# 35344551

On cusp of exponential growth with 5% mo-over-mo rev growth?

On cusp of exponential growth with 5% mo-over-mo rev growth?
2022 ended with 5% month-over-month revenue growth, that the company claims should be maintained or exceeded in 2023. Simple math (5% x 12) puts that at 60% growith for the year, but 5% compounded 12 times comes out at about 80% over a year. Should they achieve a 6% month-over-month revenue growth rate that compounds to 100% growth per year - hence my use of the term exponential.

To my mind it's taken a strangely long time to get to this point, given the advantages over surgery and radiation. But the medical professionals involved can be a conservative lot. Apparently those giving the treatments have often tempered their enthusiasm with a desire to actually see the clincal trial results replicated with their own patients. As these personal confirmations of efficacy are taking place, perhaps we'll finally see exponential growth.

-GLTA 
<< Previous
Bullboard Posts
Next >>